Truist Financial
MBRX icon

Truist Financial’s Moleculin Biotech MBRX Stock Holding History

Truist Financial’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-420
Closed -$5.57K – 2822
2025
Q3 		$5.57K Hold
420
– – ﹤0.01% 2707
2025
Q2 		$3.17K Hold
420
– – ﹤0.01% 2590
2025
Q1 		$10.2K Hold
420
– – ﹤0.01% 2534
2024
Q4 		$17.9K Hold
420
– – ﹤0.01% 2499
2024
Q3 		$29.8K Buy
+420
New +$30.3K ﹤0.01% 2466
2021
Q4 		– Sell
-78
Closed -$88K – 2803
2021
Q3 		$88K Hold
78
– – ﹤0.01% 2649
2021
Q2 		$107K Hold
78
– – ﹤0.01% 2649
2021
Q1 		$119K Hold
78
– – ﹤0.01% 2567
2020
Q4 		$139K Hold
78
– – ﹤0.01% 2437
2020
Q3 		$142K Buy
78
+16
+26% +$34K ﹤0.01% 2318
2020
Q2 		$135K Hold
62
– – ﹤0.01% 2256
2020
Q1 		$85K Hold
62
– – ﹤0.01% 2265
2019
Q4 		$128K Hold
62
– – ﹤0.01% 2402
2019
Q3 		$155K Hold
62
– – ﹤0.01% 765
2019
Q2 		$175K Hold
62
– – ﹤0.01% 760
2019
Q1 		$113K Buy
62
+22
+55% +$65.5K ﹤0.01% 757
2018
Q4 		$94K Hold
40
– – ﹤0.01% 748
2018
Q3 		$144K Hold
40
– – ﹤0.01% 762
2018
Q2 		$161K Hold
40
– – ﹤0.01% 743
2018
Q1 		$162K Hold
40
– – ﹤0.01% 741
2017
Q4 		$167K Hold
40
– – ﹤0.01% 773
2017
Q3 		$215K Hold
40
– – ﹤0.01% 744
2017
Q2 		$168K Buy
40
+22
+122% +$47.9K ﹤0.01% 759
2017
Q1 		$47K Buy
18
+9
+100% +$31.5K ﹤0.01% 814
2016
Q4 		$46K Buy
+9
New +$60.3K ﹤0.01% 823

Other funds holding MBRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Truist Financial's MBRX Position: Q4 2025 in Review

Truist Financial sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 420 shares — an estimated $5.57K sold.

Truist Financial first reported a position in MBRX in Q4 2016 and held it in 25 quarters. The position peaked at $215K in Q3 2017. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

  • Truist Financial reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
  • Truist Financial sold 420 Moleculin Biotech shares in Q4 2025, an estimated $5.57K.
  • Truist Financial first reported a position in Moleculin Biotech in Q4 2016 and held it in 25 quarters.
  • Truist Financial's Moleculin Biotech position peaked at $215K in Q3 2017.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Truist Financial's 13F filing for Q4 2025, filed 2 Feb 2026.